Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Two Street analysts weigh in on Amgen's phase 2 MariTide data, saying that they would like to see additional details on the ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.

Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...